VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
BYSIBeyondSpring Inc.
$1.61$66M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist

BYSI logoBeyondSpring Inc.(BYSI)Earnings, Financials & Key Ratios

BYSI•NASDAQ
Price updated Jun 17, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryOncology Therapeutics Developers
AboutBeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.Show more
  • Revenue$0
  • EBITDA-$9M-4.6%
  • Net Income-$8M+28.1%
  • EPS (Diluted)-0.20+28.6%

BYSI Key Insights

BeyondSpring Inc. (BYSI) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Strong 5Y profit CAGR of 33.4%
  • ✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

  • ✗Weak Piotroski F-Score: 2/9
  • ✗Trading more than 30% below 52-week high
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Get notified when BYSI posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

BYSI Price & Volume

BeyondSpring Inc. (BYSI) stock price & volume — 10-year historical chart

Loading chart...

BYSI Growth Metrics

BeyondSpring Inc. (BYSI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years-
3 Years-
TTM100%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-153.47%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-146.3%

Return on Capital

10 Years-192.62%
5 Years-59.32%
3 Years-49.3%
Last Year-50.17%

BYSI Recent Earnings

BeyondSpring Inc. (BYSI) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 3/12 qtrs (100%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 13, 2026
Metric
Actual
Est
EPS
$0.05+90.7%
$0.54
Rev
—
$9M
Q2 2026
Mar 25, 2026
Metric
Actual
Est
EPS
$0.05+90.3%
$0.54
Rev
—
—
Q4 2025
Nov 12, 2025
Metric
Actual
Est
EPS
$0.05
—
Rev
—
—
Q3 2025
Aug 13, 2025
Metric
Actual
Est
EPS
$0.04
—
Rev
—
—
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 13, 2026
$0.05vs $0.54+90.7%
—vs $9M
Q2 2026Mar 25, 2026
$0.05vs $0.54+90.3%
—
Q4 2025Nov 12, 2025
$0.05
—
Q3 2025Aug 13, 2025
$0.04
—
Based on last 12 quarters of dataView full earnings history →

BYSI Peer Comparison

BeyondSpring Inc. (BYSI) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
Institutional Holdings
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
HALO logoHALOHalozyme Therapeutics, Inc.Direct Competitor8.13B68.5726.7937.55%23.13%126.27%43.89
TGTX logoTGTXTG Therapeutics, Inc.Direct Competitor7.88B51.5018.5987.32%65.95%87.36%0.40
ACAD logoACADACADIA Pharmaceuticals Inc.Direct Competitor3.7B21.609.4311.87%34.3%35.65%0.04
PTCT logoPTCTPTC Therapeutics, Inc.Direct Competitor6.51B78.5310.09114.51%-22.58%
IMVT logoIMVTImmunovant, Inc.Direct Competitor7.13B34.71-12.53-68.16%0.00
KPTI logoKPTIKaryopharm Therapeutics Inc.Direct Competitor80.25M9.40-0.520.57%-129.02%
MGNX logoMGNXMacroGenics, Inc.Product Competitor251.71M3.96-3.360.78%-44.79%-147.8%1.92
NKTR logoNKTRNektar TherapeuticsProduct Competitor1.19B60.92-6.26-43.89%-284.18%-87%1.66

Compare BYSI vs Peers

BeyondSpring Inc. (BYSI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs HALO

Most directly comparable listed peer for BYSI.

Scale Benchmark

vs IQV

Larger-name benchmark to compare BYSI against a more recognizable public peer.

Peer Set

Compare Top 5

vs HALO, TGTX, ACAD, PTCT

BYSI Income Statement

BeyondSpring Inc. (BYSI) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Sales/Revenue
000180K1.35M1.35M0000
Revenue Growth %
----650.56%0%-100%--100%
Cost of Goods Sold
32K48K77K000302K087K19K
COGS % of Revenue
----------
Gross Profit
-32K▲ 0%
-48K▼ 50.0%
-77K▼ 60.4%
180K▲ 333.8%
1.35M▲ 650.6%
1.35M▲ 0.0%
-302K▼ 122.4%
0▲ 100.0%
-87K▲ 0%
-19K▲ 0%
Gross Margin %
---100%100%100%----
Gross Profit Growth %
-77.78%-50%-60.42%333.77%650.56%0%-122.35%100%--
Operating Expenses
97.98M57.55M40.23M64.39M67.59M38.59M14.78M8.75M8.86M8.55M
OpEx % of Revenue
---35772.78%5003.03%2856.4%----
Selling, General & Admin
9.05M5.93M8.89M22.6M30.7M13.01M7.51M6.11M4.56M3.98M
SG&A % of Revenue
---12554.44%2272.61%962.84%----
Research & Development
88.93M51.62M31.34M41.79M36.89M25.58M7.27M2.64M4.39M4.59M
R&D % of Revenue
---23218.33%2730.42%1893.56%----
Other Operating Expenses
918K315K000000-87K-19K
Operating Income
-97.98M▲ 0%
-57.55M▲ 41.3%
-40.31M▲ 30.0%
-64.21M▼ 59.3%
-66.24M▼ 3.2%
-37.24M▲ 43.8%
-15.08M▲ 59.5%
-8.75M▲ 42.0%
-8.95M▼ 2.2%
-8.57M▲ 0%
Operating Margin %
----35672.78%-4903.03%-2756.4%----
Operating Income Growth %
-692.21%41.27%29.96%-59.3%-3.16%43.78%59.5%41.95%-2.18%-
EBITDA
-97.95M-57.5M-40.23M-64.13M-66.18M-36.09M-14.78M-8.47M-8.86M-8.36M
EBITDA Margin %
----35630%-4898.52%-2671.72%----
EBITDA Growth %
-693.11%41.3%30.03%-59.42%-3.19%45.46%59.06%42.7%-4.59%-13.57%
D&A (Non-Cash Add-back)
32K48K77K77K61K1.14M302K285K87K204K
EBIT
-96.39M-57.47M-40.13M-63.74M-64.55M-36.1M-13.92M-8.75M-8.95M-8.57M
Net Interest Income
120K211K-22K31K11K178K421K59K78K69K
Interest Income
120K211K184K116K98K195K421K59K78K69K
Interest Expense
00206K85K87K17K0000
Other Income/Expense
1.59M71K-26K390K1.6M1.12M1.16M-15K320K347K
Pretax Income
-96.39M▲ 0%
-57.47M▲ 40.4%
-40.33M▲ 29.8%
-63.82M▼ 58.2%
-64.64M▼ 1.3%
-36.12M▲ 44.1%
-13.92M▲ 61.5%
-8.77M▲ 37.0%
-8.63M▲ 1.6%
-8.22M▲ 0%
Pretax Margin %
----35456.11%-4784.46%-2673.35%----
Income Tax
00003.57M163K92K96K90K262K
Effective Tax Rate %
0%0%0%0%-5.52%-0.45%-0.66%-1.09%-1.04%-3.19%
Net Income
-91.76M▲ 0%
-54.87M▲ 40.2%
-38.09M▲ 30.6%
-60.97M▼ 60.1%
-64.18M▼ 5.3%
-33.28M▲ 48.1%
-21.03M▲ 36.8%
-11.12M▲ 47.1%
-7.99M▲ 28.1%
-7.64M▲ 0%
Net Margin %
----33873.89%-4750.48%-2463.29%----
Net Income Growth %
-664.06%40.21%30.59%-60.1%-5.26%48.15%36.82%47.1%28.15%-153.47%
Net Income (Continuing)
-96.39M-57.47M-40.33M-63.82M-68.21M-36.28M-14.02M-8.87M-8.71M-8.48M
Discontinued Operations
000000-7.93M-2.65M481K-1.7M
Minority Interest
960K-1.62M854K3.48M-5.76M2.97M3.34M18.61M8.17M4.13M
EPS (Diluted)
-4.40▲ 0%
-2.42▲ 45.0%
-1.55▲ 36.0%
-2.04▼ 31.6%
-1.64▲ 19.6%
-0.85▲ 48.2%
-0.54▲ 36.5%
-0.28▲ 48.1%
-0.20▲ 28.6%
-0.19▲ 0%
EPS Growth %
-519.72%45%35.95%-31.61%19.61%48.17%36.47%48.15%28.57%-146.3%
EPS (Basic)
-4.40-2.42-1.55-2.04-1.64-0.85-0.54-0.28-0.20-
Diluted Shares Outstanding
20.87M22.67M24.65M29.98M39.02M39.09M39M39.73M40.41M41.12M
Basic Shares Outstanding
20.87M22.67M24.65M29.98M39.02M39.09M39M39.73M40.41M41.12M
Dividend Payout Ratio
----------

BYSI Balance Sheet

BeyondSpring Inc. (BYSI) balance sheet — assets, liabilities & shareholders' equity

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Total Current Assets
32.34M5.87M40.86M113.4M75.12M38.52M18.42M28.58M20.88M13.5M
Cash & Short-Term Investments
30.55M3.89M35.93M109.54M72.37M37.27M15.34M2.92M12.56M7.86M
Cash Only
27.48M3.89M35.93M109.54M41.63M34.4M15.34M2.92M7.79M4.04M
Short-Term Investments
3.07M00030.74M2.87M004.78M3.83M
Accounts Receivable
0000000000
Days Sales Outstanding
----------
Inventory
01.21M00000000
Days Inventory Outstanding
-9.19K--------
Other Current Assets
264K1.69M410K358K1.02M763K2.79M25.41M8.32M5.64M
Total Non-Current Assets
484K1.19M3.69M3.64M6.53M7.7M6.39M5.74M5.05M4.9M
Property, Plant & Equipment
123K282K2.75M2.36M4.95M7.35M1.05M752K471K392K
Fixed Asset Turnover
---0.08x0.27x0.18x---0.00x
Goodwill
0000000000
Intangible Assets
0000000000
Long-Term Investments
0000000000
Other Non-Current Assets
361K910K946K1.28M1.57M347K5.34M4.99M4.58M4.51M
Total Assets
32.83M▲ 0%
7.06M▼ 78.5%
44.55M▲ 530.8%
117.04M▲ 162.7%
81.65M▼ 30.2%
46.22M▼ 43.4%
24.81M▼ 46.3%
34.31M▲ 38.3%
25.93M▼ 24.4%
18.41M▲ 0%
Asset Turnover
---0.00x0.02x0.03x---0.00x
Asset Growth %
120.2%-78.48%530.82%162.68%-30.24%-43.39%-46.33%38.32%-24.43%-40.35%
Total Current Liabilities
4.79M16.45M10.05M13.77M15.15M7.35M7.96M11.01M13.58M12.37M
Accounts Payable
3.38M9.59M2.54M2.22M1.66M1.08M561K295K363K646K
Days Payables Outstanding
38.54K72.89K12.03K---678.03-1.52K7.58K
Short-Term Debt
0029K01.57M0258K0320K246K
Deferred Revenue (Current)
006.88M1.35M1.37M1.35M1.75M27.4M28.6M85.51M
Other Current Liabilities
606K1.36M-6.02M2.95M6.17M1.45M4.4M-17.58M-15.71M-17.52M
Current Ratio
6.75x0.36x4.06x8.24x4.96x5.24x2.31x2.60x1.54x1.09x
Quick Ratio
6.75x0.28x4.06x8.24x4.96x5.24x2.31x2.60x1.54x1.09x
Cash Conversion Cycle
----------
Total Non-Current Liabilities
3.38M9.59M3.37M11.45M45.57M41.88M40.31M37.59M36.35M36.39M
Long-Term Debt
001.44M2.17M000000
Capital Lease Obligations
001.94M1.36M1.47M4M589K307K0263K
Deferred Tax Liabilities
00005.45M00000
Other Non-Current Liabilities
0000709K3.66M11.55M9.88M7.75M36.39M
Total Liabilities
4.79M16.45M13.42M25.22M60.73M49.23M48.27M48.6M49.92M48.76M
Total Debt
003.94M4.31M3.58M4.96M847K589K320K246K
Net Debt
-27.48M-3.89M-32M-105.22M-38.05M-29.43M-14.49M-2.33M-7.47M-3.79M
Debt / Equity
--0.13x0.05x0.17x-----0.01x
Debt / EBITDA
----------0.03x
Net Debt / EBITDA
---------0.45x
Interest Coverage
---194.79x-749.84x-741.97x-2123.53x----
Total Equity
28.04M▲ 0%
-9.38M▼ 133.5%
31.13M▲ 431.8%
91.82M▲ 195.0%
20.92M▼ 77.2%
-3.01M▼ 114.4%
-23.46M▼ 680.2%
-14.29M▲ 39.1%
-23.99M▼ 67.9%
-30.35M▲ 0%
Equity Growth %
127.95%-133.46%431.82%194.95%-77.21%-114.37%-680.21%39.11%-67.94%-213.02%
Book Value per Share
1.34-0.411.263.060.54-0.08-0.60-0.36-0.59-0.74
Total Shareholders' Equity
27.08M-7.77M30.28M88.34M26.68M-5.98M-26.8M-32.9M-32.16M-34.49M
Common Stock
2K2K3K4K4K4K4K4K4K4K
Retained Earnings
-123.89M-178.76M-216.84M-277.82M-342M-375.28M-396.3M-407.43M-408.43M-410.59M
Treasury Stock
0000000000
Accumulated OCI
-182K42K140K-297K-523K436K894K1.34M602K360K
Minority Interest
960K-1.62M854K3.48M-5.76M2.97M3.34M18.61M8.17M4.13M

BYSI Cash Flow Statement

BeyondSpring Inc. (BYSI) cash flow — operating, investing & free cash flow history

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Cash from Operations
-28.8M-39.95M-48.16M-43.74M-47.24M-28.15M-16.47M-16.44M-20.02M-19.09M
Operating CF Margin %
----24302.78%-3496.82%-2083.72%----
Operating CF Growth %
-110.22%-38.75%-20.54%9.17%-7.99%40.41%41.48%0.19%-21.77%26.39%
Net Income
-96.39M-57.47M-38.09M-63.82M-68.21M-36.28M-21.03M-11.12M-8.47M-7.64M
Depreciation & Amortization
32K48K77K77K61K232K302K285K87K144K
Stock-Based Compensation
22.68M6.56M08.19M3.15M1.67M554K2.06M0145K
Deferred Taxes
0000-1.2M00000
Other Non-Cash Items
42.26M-307K-147K659K546K-178K988K-6.29M-11.26M-13.46M
Working Capital Changes
2.62M11.22M-10.01M11.15M18.41M6.41M2.71M-1.38M-376K2.26M
Change in Receivables
00481K0-1.77M00000
Change in Inventory
-726K316K-3.31M01.77M0186K-19K-18K58.74K
Change in Payables
2.94M6.21M-7.05M-321K-560K-575K00-76K4.33M
Cash from Investing
-3.15M2.87M10.08M-52K-20.41M18.25M-100K-12.01M13.48M12.07M
Capital Expenditures
-76K-207K-4K-52K-2.84M-34K-100K-224K-50K-541
CapEx % of Revenue
---28.89%210.51%2.52%----
Acquisitions
0010.08M020.41M00010.05M3.09M
Investments
----------
Other Investing
-3.07M3.07M00-20.41M717K0-11.79M010.85M
Cash from Financing
47.72M13.24M70.09M117.83M1K3.43M4K26.79M2.27M-2.13M
Debt Issued (Net)
001.52M606K0-1.57M03.91M286K-4.42M
Equity Issued (Net)
50.51M14M68.57M112.58M39K0001.99M2.01M
Dividends Paid
0000000000
Share Repurchases
0000000000
Other Financing
-2.78M-755K04.65M-38K5M4K22.87M0283.51K
Net Change in Cash
15.79M▲ 0%
-23.59M▼ 249.4%
32.04M▲ 235.8%
73.6M▲ 129.7%
-67.91M▼ 192.3%
-7.23M▲ 89.4%
-16.65M▼ 130.3%
-1.7M▲ 89.8%
4.86M▲ 385.6%
-539K▲ 0%
Free Cash Flow
-28.87M▲ 0%
-40.16M▼ 39.1%
-48.17M▼ 19.9%
-43.8M▲ 9.1%
-50.09M▼ 14.4%
-28.18M▲ 43.7%
-16.57M▲ 41.2%
-16.67M▼ 0.6%
-20.07M▼ 20.4%
-19.09M▲ 0%
FCF Margin %
----24331.67%-3707.33%-2086.23%----
FCF Growth %
-109.8%-39.1%-19.93%9.07%-14.36%43.73%41.2%-0.56%-20.44%-324.14%
FCF per Share
-1.38-1.77-1.95-1.46-1.28-0.72-0.43-0.42-0.50-0.46
FCF Conversion (FCF/Net Income)
0.31x0.73x1.26x0.72x0.74x0.85x0.78x1.48x2.51x2.50x
Interest Paid
00085K91K17K0000
Taxes Paid
000022K367K002K1K

BYSI Key Ratios

BeyondSpring Inc. (BYSI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric201720182019202020212022202320242025TTM
Return on Equity (ROE)
-455%-588.28%-350.22%-99.18%-113.85%-371.5%---33.34%
Return on Invested Capital (ROIC)
-10673.31%--------20.71%
Gross Margin
---100%100%100%----
Net Margin
----33873.89%-4750.48%-2463.29%----
Debt / Equity
--0.13x0.05x0.17x-----0.01x
Interest Coverage
---194.79x-749.84x-741.97x-2123.53x----
FCF Conversion
0.31x0.73x1.26x0.72x0.74x0.85x0.78x1.48x2.51x2.50x
Revenue Growth
----650.56%0%-100%--100%
Related:BYSI Dividend History·BYSI Revenue History·BYSI Price History·BYSI P/E History·BYSI Financial Ratios·BYSI Institutional Holders

BYSI SEC Filings & Documents

BeyondSpring Inc. (BYSI) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 13, 2026·SEC

Material company update

Mar 25, 2026·SEC

Material company update

Dec 15, 2025·SEC

10-K Annual Reports

2
FY 2026

Mar 25, 2026·SEC

FY 2025

Mar 27, 2025·SEC

10-Q Quarterly Reports

4
FY 2026

May 13, 2026·SEC

FY 2025

Nov 12, 2025·SEC

FY 2025

Aug 13, 2025·SEC

BYSI Frequently Asked Questions

BeyondSpring Inc. (BYSI) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

BeyondSpring Inc. (BYSI) grew revenue by 0.0% over the past year. Growth has been modest.

BeyondSpring Inc. (BYSI) reported a net loss of $7.6M for fiscal year 2025.

Dividend & Returns

BeyondSpring Inc. (BYSI) had negative free cash flow of $19.1M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in BYSI back in 2014?

Total return calculator · dividends reinvested · 12+ years of data

See returns →

How much would $100/month in BYSI be worth today?

Dollar cost averaging calculator · DCA vs lump sum

Calculate →